Please try another search
For the fiscal year ended 31 December 2018, Tai-Ling Biotech Inc revenues increased 3% to NT$341.8M. Net income totaled NT$12.2M vs. loss of NT$35.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Other Trading Income, Net increase from NT$20.9M to NT$88.4M (income), Sale of Fixed Assets - Gain/Loss decrease of 58% to NT$9.4M (expense).
Period Ending: | Dec 31, 2018 | Jun 30, 2018 | Dec 31, 2017 | Jun 30, 2017 |
---|---|---|---|---|
Total Revenue | 186.18 | 155.63 | 179.98 | 150.3 |
Gross Profit | 4.1 | 10.77 | 23.78 | 11.07 |
Operating Income | 8.48 | 1.74 | -19.81 | 0.71 |
Net Income | 9.73 | 2.47 | -33.96 | -1.19 |
Period Ending: | Dec 31, 2018 | Jun 30, 2018 | Dec 31, 2017 | Jun 30, 2017 |
---|---|---|---|---|
Total Assets | 890.69 | 902.91 | 865.8 | 888.66 |
Total Liabilities | 213.5 | 235.41 | 201.12 | 186.52 |
Total Equity | 677.19 | 667.5 | 664.67 | 702.14 |
Period Ending: | Dec 31, 2018 | Jun 30, 2018 | Dec 31, 2017 | Jun 30, 2017 |
---|---|---|---|---|
Period Length: | 12 Months | 6 Months | 12 Months | 6 Months |
Cash From Operating Activities | 73.66 | 34.61 | 42.78 | 5.42 |
Cash From Investing Activities | -107.23 | -72.75 | -111 | -57.19 |
Cash From Financing Activities | 17.31 | 24.89 | 59.93 | 47.24 |
Net Change in Cash | -17.38 | -12.36 | -13.12 | -4.53 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review